GO:0042558Ontology (GO BP)GO biological process · ~33 member genes
Q-omics provides the Pteridine-containing compound metabolic process (GO:0042558) pathway profile, scoring each patient from the combined activity of its roughly 33 member genes. Pathway activity is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, the pathway is differentially active in 13, with the highest sampling consensus in HNSC. Additionally, pathway RNA activity shows 36,729 significant cross-omics associations, again with the highest sampling consensus in HNSC. Together, these results highlight LGG, and HNSC as cancer lineages where the pathway shows reproducible signals across outcome, tissue activity, and molecular association analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns. Pathway-against-pathway and pathway-against-mutation comparisons are not available for ontology entities.
Survival associations
This table summarizes Pteridine-containing compound metabolic process survival associations by molecular data type. RNA-level pathway activity shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each layer.
This table ranks reproducible pathway activity–survival associations across cancer types. High Pteridine-containing compound metabolic process activity shows favorable associations in MESO, but unfavorable associations in LGG, CHOL, ACC, KICH and UVM. In the LGG Kaplan–Meier curve the high-activity group declines faster, consistent with the unfavorable association (log-rank p < 0.001). LGG ranks highest by sampling consensus for Pteridine-containing compound metabolic process.
This table summarizes Pteridine-containing compound metabolic process tumor–normal activity differences by data type. RNA-level activity shows significant tumor–normal differences in 13 cancer types, while mass-spec protein activity shows differences in 4. The strongest signals are in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal activity differences for the pathway. A positive fold-change indicates higher activity in tumor tissue. The pathway shows higher tumor activity across HNSC, COAD, BLCA, KIRC and UCEC and lower tumor activity in KICH. In the HNSC box plot, tumor samples show higher pathway activity than matched normal samples (log2 FC = +0.028, t-test p = .001).
This table shows molecular features associated with Pteridine-containing compound metabolic process pathway activity in patient tissues and cancer cell lines. In patient samples, pathway activity is most strongly linked to RNA and protein features, with the largest associated set in HNSC. In cancer cell lines, RNA-expression features and functional dependencies dominate, with the largest set in BONE.
